Heidi Nelson to Breast Neoplasms
This is a "connection" page, showing publications Heidi Nelson has written about Breast Neoplasms.
Connection Strength
6.650
-
Patient Navigation Services for Breast and Cervical Cancer Screening and Follow-Up: A Meta-Analysis. JAMA Intern Med. 2025 Aug 01; 185(8):976-985.
Score: 0.554
-
Use of an Online Breast Cancer Risk Assessment and Patient Decision Aid in Primary Care Practices. J Womens Health (Larchmt). 2020 06; 29(6):763-769.
Score: 0.381
-
Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2019 09 03; 322(9):868-886.
Score: 0.367
-
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2019 08 20; 322(7):666-685.
Score: 0.366
-
Mammography Screening and Overdiagnosis. JAMA Oncol. 2016 Feb; 2(2):261-2.
Score: 0.287
-
Effectiveness of Breast Cancer Screening: Systematic Review and Meta-analysis to Update the 2009 U.S. Preventive Services Task Force Recommendation. Ann Intern Med. 2016 Feb 16; 164(4):244-55.
Score: 0.285
-
Harms of Breast Cancer Screening: Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation. Ann Intern Med. 2016 Feb 16; 164(4):256-67.
Score: 0.285
-
Factors Associated With Rates of False-Positive and False-Negative Results From Digital Mammography Screening: An Analysis of Registry Data. Ann Intern Med. 2016 Feb 16; 164(4):226-35.
Score: 0.285
-
Mammography Decision Aid Reduces Decisional Conflict for Women in Their Forties Considering Screening. J Womens Health (Larchmt). 2015 Dec; 24(12):1013-20.
Score: 0.279
-
Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med. 2014 Feb 18; 160(4):255-66.
Score: 0.250
-
Rates and indications for surgical breast biopsies in a community-based health system. Am J Surg. 2014 Apr; 207(4):499-503.
Score: 0.246
-
Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013 Apr 16; 158(8):604-14.
Score: 0.236
-
Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med. 2012 May 01; 156(9):635-48.
Score: 0.221
-
Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Ann Intern Med. 2009 Nov 17; 151(10):703-15, W-226-35.
Score: 0.186
-
Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2009 Nov 17; 151(10):727-37, W237-42.
Score: 0.186
-
Estimating risk of breast cancer in carriers of BRCA1 and BRCA2 mutations: a meta-analytic approach. Stat Med. 2007 Apr 15; 26(8):1775-87.
Score: 0.156
-
Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2005 Sep 06; 143(5):362-79.
Score: 0.139
-
Recommendations From the Women's Preventive Services Initiative on Breast Cancer Screening for Women at Average Risk and Patient Navigation Services for Breast and Cervical Cancer Screening. Obstet Gynecol. 2025 Jul 17; 146(3):315-322.
Score: 0.138
-
Postpartum Breast Cancer and Survival in Women With Germline BRCA Pathogenic Variants. JAMA Netw Open. 2024 Apr 01; 7(4):e247421.
Score: 0.126
-
Evaluating information loss in the National Cancer Database from cases lost to follow-up. J Surg Oncol. 2022 Nov; 126(6):1123-1132.
Score: 0.113
-
Extrapolation of ACOSOG Z0011 trial results-A survey of breast cancer providers. Breast J. 2021 06; 27(6):537-542.
Score: 0.102
-
Uptake of Breast Cancer Clinical Trials at Minority Serving Cancer Centers. Ann Surg Oncol. 2021 Sep; 28(9):4995-5004.
Score: 0.101
-
Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. Breast Cancer Res Treat. 2020 Jun; 181(3):487-497.
Score: 0.096
-
Second opinion strategies in breast pathology: a decision analysis addressing over-treatment, under-treatment, and care costs. Breast Cancer Res Treat. 2018 01; 167(1):195-203.
Score: 0.080
-
The diagnostic challenge of low-grade ductal carcinoma in situ. Eur J Cancer. 2017 07; 80:39-47.
Score: 0.078
-
Surgical implications and variability in the use of the flat epithelial atypia diagnosis on breast biopsy specimens. Breast. 2017 Aug; 34:34-43.
Score: 0.078
-
Diagnostic Reproducibility: What Happens When the Same Pathologist Interprets the Same Breast Biopsy Specimen at Two Points in Time? Ann Surg Oncol. 2017 May; 24(5):1234-1241.
Score: 0.076
-
Evaluation of 12 strategies for obtaining second opinions to improve interpretation of breast histopathology: simulation study. BMJ. 2016 Jun 22; 353:i3069.
Score: 0.074
-
The Influence of Disease Severity of Preceding Clinical Cases on Pathologists' Medical Decision Making. Med Decis Making. 2017 01; 37(1):91-100.
Score: 0.072
-
Variability in Pathologists' Interpretations of Individual Breast Biopsy Slides: A Population Perspective. Ann Intern Med. 2016 05 17; 164(10):649-55.
Score: 0.072
-
Diagnostic concordance among pathologists interpreting breast biopsy specimens. JAMA. 2015 Mar 17; 313(11):1122-32.
Score: 0.067
-
Trends in breast biopsy pathology diagnoses among women undergoing mammography in the United States: a report from the Breast Cancer Surveillance Consortium. Cancer. 2015 May 01; 121(9):1369-78.
Score: 0.067
-
Comparative effectiveness of imaging modalities to determine metastatic breast cancer treatment response. Breast. 2015 Feb; 24(1):3-11.
Score: 0.066
-
Digitized whole slides for breast pathology interpretation: current practices and perceptions. J Digit Imaging. 2014 Oct; 27(5):642-8.
Score: 0.065
-
Second opinion in breast pathology: policy, practice and perception. J Clin Pathol. 2014 Nov; 67(11):955-60.
Score: 0.064
-
A framework for evaluating diagnostic discordance in pathology discovered during research studies. Arch Pathol Lab Med. 2014 Jul; 138(7):955-61.
Score: 0.064
-
Modification of breast cancer risk according to age and menopausal status: a combined analysis of five population-based case-control studies. Breast Cancer Res Treat. 2014 May; 145(1):165-75.
Score: 0.063
-
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013 Oct 09; 310(14):1455-61.
Score: 0.061
-
Development of a diagnostic test set to assess agreement in breast pathology: practical application of the Guidelines for Reporting Reliability and Agreement Studies (GRRAS). BMC Womens Health. 2013 Feb 05; 13:3.
Score: 0.058
-
Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Preventive Services Task Force recommendations. Ann Intern Med. 2012 Jul 17; 157(2):104-13.
Score: 0.056
-
Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk. Ann Intern Med. 2012 May 01; 156(9):609-17.
Score: 0.055
-
Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002 Aug 21; 288(7):872-81.
Score: 0.028
-
Models in the development of clinical practice guidelines. Ann Intern Med. 2014 Dec 02; 161(11):812-8.
Score: 0.017